Core Viewpoint - Allogene Therapeutics is actively participating in the Citi's 2025 Biopharma Back to School Summit, showcasing its commitment to advancing allogeneic CAR T products for cancer and autoimmune diseases [1] Company Overview - Allogene Therapeutics is a clinical-stage biotechnology company based in South San Francisco, focusing on the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune diseases [2] - The company aims to create a pipeline of "off-the-shelf" CAR T cell product candidates, providing readily available cell therapy on-demand, more reliably, and at greater scale to a larger patient population [2] Investor Relations - The company will provide webcasts of the investor conference, with replays available on its website for approximately 30 days [1]

Company Overview - Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune diseases [4] - The company aims to provide "off-the-shelf" CAR T cell product candidates that are readily available, reliable, and scalable for patient treatment [4] Upcoming Events - Allogene Therapeutics will report its second quarter 2025 financial results and provide a business update on August 13, 2025, after market close [1] - A live audio webcast and conference call will follow the announcement at 2:00 p.m. PT/5:00 p.m. ET [1] Webcast Information - The listen-only webcast will be available on the company's website under the Investors tab in the News and Events section, with a replay accessible for approximately 30 days [2] - Registration is required for those who wish to ask questions during the conference call, and participants will receive a personal PIN upon registration [3]

Core Insights - Allogene Therapeutics has selected standard fludarabine and cyclophosphamide (FC) as the lymphodepletion regimen for its ALPHA3 study evaluating cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma (LBCL) [1][6] - The ALPHA3 trial has shifted to a randomized study design comparing cema-cel after standard FC lymphodepletion to observation, with a futility analysis expected in the first half of 2026 [4][6] Company Developments - The decision to close the arm testing FC plus ALLO-647 was made due to a Grade 5 adverse event attributed to ALLO-647, leading to a review of trial data and a shift in clinical strategy [2][3] - Allogene is advancing next-generation AlloCAR T product candidates using the proprietary Dagger® Platform Technology, which aims to minimize or eliminate the need for standard lymphodepletion [3][6] Clinical Trial Details - The ALPHA3 study is designed to treat over 60,000 patients annually for LBCL in the US, EU, and UK, with cema-cel positioned as a potential standard "7th cycle" treatment following initial chemotherapy [8] - The trial has over 50 clinical sites activated across the US and Canada, including community cancer centers and major academic institutions [4][6] Product Information - Cemacabtagene ansegedleucel (cema-cel) is an investigational anti-CD19 AlloCAR T™ product for LBCL, with oncology rights held by Allogene in the US, EU, and UK, and options for rights in China and Japan [7][9]

Conference Call and Webcast Scheduled for May 13, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report the first quarter 2025 financial results and provide a business update on May 13, 2025, after the close of the market. The announcement will be ...